Pharma Turkey Dergisi Eylül – Ekim 2017 Sayısı

More documents

Recommendations

Info

We can now transfer to any patient who needs transplantation. Turkey also transport of full donor transplant centers are increasingly incompatible "haploidentical transplants" in the field showed that he was quite successful.” Referring to Living Drug Approach, Prof. Dr. Seckin Cagırgan said, “The patient has some treatment approaches to using leukemia cells to transform them into cells that fight against leukemia cells by processing them in the experimental environment. CR-T cell we call the new method of treatment is a very important therapeutic approach in this regard. In our country, we can make it to the agenda and how we can put these treatments into practice he spoke Prof. Dr. Ercument Ovalı has taken the lead role in this issue. We invited him to share his experiences with the 4th Hematological Oncology Congress.” purified from the body. As a result, some diseases may have a familial tendency, but it has become possible to recognize the genetic defect in the developing cell, to determine how to deal with the disease according to this genetic claim, and to make the treatment intervention according to this situation.” Professor who emphasized the importance of correct diagnosis repeatedly and invited the pathologists from the group of physicians who have the main role in diagnosis of the Congress for this purpose. Dr. Sevgi Kalayoglu Besısık said, "Hematologists work with physicians in multiple areas of expertise. One of the most important are the pathologist. Biopsy of the importance of taking part in what we call right and adequate supply of the diagnosis, early treatment' Tell me the date and the place was' left early, accurate diagnosis to treatment to specific patients.” When the patients participate in scientific studies, the concept of 'guinea pig' must be destroyed ... Expressing that the 21st century medicine brought the concept of private treatment to the agenda, Assoc. Dr. Emre Tekgündüz, "This concept is extremely important. Now we are talking about the individualistic dress that a tailor has sewed, rather than a mass-produced suitcase that is more or less suitable for everyone's body. As scientists dealing with cancer treatment, we are constantly giving various percentages about the treatment possibilities of 14 Pharma September- October ‘17 'Early Diagnosis of Early Treatment', the Place ', but early diagnosis and correct treatment Drop Patient-Specific ... Multiple speech myeloma, Waldenstrom macroglobulinemia, such as amyloidosis, a rare disease that starts by mentioning the HOD Vice President Prof. Dr. Sevgi Kalayoglu Besısık, said, “learning by monitoring the cancer diagnosis of patients they are most interested in" Why me? "Is the answer to the question. In this meeting, the place of the immune system, the genetic basis of diseases, the molecular space were discussed in cancer development. We emphasized the importance of risk factors, that is, situations that could negatively affect the course of the disease. The time will come when the illness comes, in fact, according to the genetic alteration in the cancer cell of the patient plan of treatment will be done. If the control of how much cancer cells decrease after treatment is based on the remnant of this genetic change, a different treatment approach will be applied if it is left in bed, and another treatment will be applied if it is value of the diagnosis and evaluation of the documents pathology of the disease must be an expert on that subject hematopathologist so we brought back on the agenda. There are such diseases that the name is cancer, but we have a disease like this and maybe we will watch you for a long time without giving any medicine. Here are a few of these diseases, chronic lymphocytic leukemia, and no evidence of multiple symptoms myeloma and WaldenstromThe macroglobulinemia. Early and correct diagnosis is also important in this respect. Because the treatment without treatment will be carried on the agenda. For that reason, evaluation of the patients with specific experience of the disease and institutional monitoring are very important. 'Early diseases. For example, when we say that a patient is 80 percent likely to recover, in other words, we can lose 20 percent of our patients. These figures apply to a group of patients with the same cancer diagnosis and risk group characteristics. In reality, most of the time for our cancer patients against all or nothing rule applies. So the patient is healing or we are losing him. The chance of 80 percent improvement in our sample does not mean that our patient will definitely improve. How real is that these statistics of the treatment process for our patients standing in front of us, gave information about the general population would end no chance pinpoint. In the treatment of hematological cancers, the genetic characteristics of cancer cells are very important.
New generation sequencing (next generation Sequencing) of cancerous and normal cells with the genetic map analysis methods able to determine a so-called very quickly and at a lower cost compared with the not the same. In a foreseeable future, we will start by removing the genetic map of the cancer cell in all of our patients and we will determine the treatment method to follow. We recommend common treatment approaches for patients with certain genetic characteristics, even if each individual has no specific treatment. Targeted treatment costs are extremely high. Participation in scientific studies needs to be increased in order for these treatments to become widespread in our country. I need to give expensive treatment to the patient group who will really benefit. Here we need to break down the concept of 'guinea pigs'. The circumstances in which a patient is treated in optimum conditions provide scientific research. There are strict controls here. Every stage is passed through the eye. The illness treated within the scope of the research with folk expression is regarded as 'hand baby rose baby'. Do not hesitate to join our patients in these scientific investigations, each stage of which is strictly controlled. But in this way they are able to get free access to costly treatment options. They are both free to use the treatment, and they have a chance to go through a much more rigorous care than a standard patient.” Turkey is preparing to test the first indigenous living medicine in cancer treatment ... Turkey's 'first domestic leather production' with the invention, one of the world's prestigious medical awards US Plastic and Reconstructive Surgery Association's awarded the prize of 'Best Experimental Research' Prof. Dr. Ercument Ovali was among the congress speakers. Professor Dr. Ercument Ovali, Turkey's first genetically modified cell therapy in the 4th Hematological Oncology Congress announced for the first time. Professor participating in the Congress of the drug treatment to live in Turkey wants to support the expression of Professor. Dr. Ercument Ovalı said, "Because you have to prepare the method of treatment in the laboratory or to show that it works on animals alone does not have any importance. This treatment method should be rapidly tested in Turkey with a clinical trial. Instead of seeing themselves as guinea pigs, they need to trust the team to be able to hold on to life and to keep others alive. This will bring us two things. Turkey will have tested the native genetically modified cell as it produces and many people will change their lives.” Living the life expectancy in some types of cancer drugs can be extended to 3 years 3 months ... Exampling Made in the USA CR-T cell the treatment that Prof. Dr. Ercument Ovalı said, "An acute lymphoblastic leukemia in children's life expectancy is resistant to any kind of treatment is less than 6 months, or even the average is around 3 months. With today's technology, you have no other chance. But with these living medicines, 95 percent of these children can achieve 3 year survival. This is a revolution. But this is not a treatment you can take from your pharmacy. They have complications. A method of treatment of hematopoietic stem cell transplant teams who can apply. That's why conventions like this allow us to build teams. We will train each other. Because the job does not end with the production in the lab. Clinical results are very important. Thank you for bringing us together for the Hematological Oncology Society. If there is no setback, we aim to start phase 1 studies in January 2018. Leukemia in three separate diseases, but will work in lymphoma patients and MyOle. We aim to practice on a total of 27 patients with 9 patients. I need the support of our doctors for this.” Turkish patients will be able to benefit much less in Turkey with half a trillion worth of treatment ... CR-T cell, a process which began approach to cost half a trillion last year at 35 centers in the United States. For many years, bone marrow transplants have shown scientists that the power to destroy a self-made cancer is less than that of any other human being. Living medicines have caused a significant change in this understanding and have begun to be used by subjecting one's own cell to genetic alteration. Thus, it began to fight cancer, as if the person's own immune cell was a micro-battle. If this technology is established in Turkey under the leadership of Turkish scientists, the cost will be much less and acceptable. The costs of treatment will go from one state to another and remain in our country. Pharma September- October ‘17 15
Page 1: September-October 2017 A
Page 4 and 5: 2 Pharma September- October ‘17
Page 6 and 7: Publisher Ferruh IŞIK on behalf of
Page 8 and 9: Akıllı ilaçlarla umutlar artıyo
Page 10 and 11: Hopes raising with smart drugs An i
Page 12 and 13: Kanser tedavisinde yeni bir seçene
Page 14 and 15: Hematolojik kanserlerin tedavisinin
Page 18 and 19: DEVA, EU GMP sertifikalı tesisleri
Page 20: DEVA receives FDA approval with EU
Page 23 and 24: Trimbow ® (ICS/LABA/LAMA) Avrupa
Page 25 and 26: The FDA-approved drug VENCLYXTO (v
Page 28 and 29: “Nükleer tıp Parkinson ve Alzhe
Page 30 and 31: “Nuclear medicine will play a ver
Page 32 and 33: Kilo vermenin dayanılmaz hafifliğ
Page 34: The unbearable lightness of weight
Page 37 and 38: Two major transfers abroad in The N
Page 40 and 41: Berko İlaç sürdürülebilirliği
Page 42 and 43: Romatoid artrit tedavisinde kullan
Page 44: Kaliteli ve Sürdürülebilir Bir S
Page 48 and 49: Türk ilacının kalitesi dünyada
Page 50: The quality of Turkish medicine is
Page 53 and 54: Uluslararası Katılımlı Ulusal S
Page 55 and 56: 2. İstanbul Ulusal Beslenme ve Diy
Page 58 and 59: Hazırlayanlar: Ebru PEKEL - Recep
Page 60 and 61: Bayraktar Grubu’nda organizasyone
Page 62 and 63: Kordsa ve Continental Güçlerini B
Page 64: İkinci El Araçta Konforun Yeni Ad

Pharma Turkey Dergisi Eylül – Ekim 2017 Sayısı

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?